-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194

Benzinga·08/03/2026 13:08:25
Listen to the news
Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $185 to $194.